• user warning: Table './fnndrupaldev/term_node' is marked as crashed and last (automatic?) repair failed query: SELECT t.* FROM term_node r INNER JOIN term_data t ON r.tid = t.tid INNER JOIN vocabulary v ON t.vid = v.vid WHERE r.vid = 421010 ORDER BY v.weight, t.weight, t.name in /var/www/www.fnno.com/htdocs/modules/taxonomy/taxonomy.module on line 617.
  • user warning: Table './fnndrupaldev/sessions' is marked as crashed and last (automatic?) repair failed query: SELECT COUNT(sid) AS count FROM sessions WHERE timestamp >= 1417031706 AND uid = 0 in /var/www/www.fnno.com/htdocs/includes/session.inc on line 111.
  • user warning: Table './fnndrupaldev/sessions' is marked as crashed and last (automatic?) repair failed query: SELECT DISTINCT u.uid, u.name, s.timestamp FROM users u INNER JOIN sessions s ON u.uid = s.uid WHERE s.timestamp >= 1417031706 AND s.uid > 0 ORDER BY s.timestamp DESC in /var/www/www.fnno.com/htdocs/modules/user/user.module on line 765.

Acadia Pharmaceuticals Shares Climbing Higher, Up 2.6%

Published on Mon, 01/14/2013 - 11:15
By Adrienne Chilton

Acadia Pharmaceuticals (NASDAQ:ACAD) is a company whose shares are active, trading 2.6% higher to $5.14. The S&P is trading lower by 0.2% to 1,469 and the Dow is trading fractionally lower to 13,484.

There is potential upside of 62.6% for shares of Acadia Pharmaceuticals based on a current price of $5.14 and an average consensus analyst price target of $8.36. The stock should find initial support at its 50-day moving average (MA) of $3.87 and further support at its 200-day MA of $2.32.

Over the past year, Acadia Pharmaceuticals has traded in a range of $1.24 to $6.54 and is now at $5.14, 315% above that low. Over the past week, the 200-day moving average (MA) has gone up 3.1% while the 50-day MA has advanced 7.4%.

Acadia Pharmaceuticals Inc. is a biopharmaceutical company focused on the discovery, development and commercialization of small molecule drugs for the treatment of central nervous system disorders. The company is currently working on the treatment of induced dysfunction in Parkinson's disease ,schizophrenia, neuropathic pain and glaucoma.

By Adrienne Chilton
achilton@fnno.com

Latest News from FNNO

Stock Investors Bid Up Shares of Silicon...

Siliconware Precision Industries (NASDAQ:SPIL) is one of today's biggest movers, up 1.2 ...

Kinder Morgan Trading Higher on 1.5x Abo...

The price of Kinder Morgan shares has climbed to $41.01 (a 0.6% change) on heavy tradin ...

Acxiom Makes a Move: Down 1.2%...

Acxiom (NASDAQ:ACXM) is one of today's notable stocks in decline, down 1.2% to $19.25. ...

Volume Spike Detected in Shares of Diamo...

Diamond Offshore Drilling shares are trading on heavy volume today, having fallen 9.4% ...

Shares of NBT Bancorp Under Pressure, Do...

NBT Bancorp (NASDAQ:NBTB) is a company whose shares are active, trading 1.2% lower to $ ...

Buyers Accumulating Shares of Analog Dev...

Analog Devices's stock is up 4.0% to $53.77 on heavy trading volume. About 3.7 million ...

Shares of Bank Mutual Under Pressure, Do...

Bank Mutual (NASDAQ:BKMU) is one of today's notable stocks in decline, down 1.2% to $6. ...

Transocean Trading Lower on 1.6x Above-A...

The price of Transocean shares has slipped to $23.85 (a 5.8% change) on heavy trading v ...